Skip to content
stoqly

Acadia Pharmaceuticals

ACAD Nasdaq Pharmaceuticals Financials FY2016–FY2025

Acadia Pharmaceuticals' revenue rose 11.9% to $1.1 billion in fiscal 2025. Its operating margin was 9.8%, down from 24.1% a year earlier. Free cash flow was $105 million, down 33.1%. The diluted share count rose 2.1%.

Last close · Oct 23, 2026

$19.73

2.9%
Value it Compare
Revenue Total sales reported in the income statement.
$1.1B
11.9% vs prior year
Operating margin Operating income as a share of revenue.
9.8%
14.3 pts
Net income Profit after all expenses, interest and tax.
$391M
72.6%
Free cash flow Cash from operations minus capital spending.
$105M
33.1%
Return on capital After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
—
Market cap Last close times the latest diluted share count, so it is approximate.
$3.4B
Oct 23 close
P/E Last close divided by diluted earnings per share over the last four quarters.
8.8x
On $2.23 EPS (TTM)

What Acadia Pharmaceuticals does

No business description yet.

Legal name
ACADIA PHARMACEUTICALS INC.
Fiscal year ends
December 31, 2025
Latest annual report
—
Accession · CIK
0001193125-26-072519
0001070494

Revenue and margins

Acadia Pharmaceuticals had $1.1B of revenue in fiscal 2025, up 11.9% on the year before.

Revenue
Revenue
Margins, % of revenue
Gross Operating Net FCF
Margins, % of revenue
Gross Operating Net FCF

Net income and earnings per share

Loss periods are shown in red.

Net income
Net income
Diluted EPS
Diluted EPS

Returns on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

Return on capital, equity and assets (annual)
Return on capital Return on equity Return on assets

Cash flow

Free cash flow was $105M in fiscal 2025, 9.8% of revenue. Cash from operations minus capital spending.

Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations Capital spending
Cash from operations vs capital spending
Cash from operations Capital spending

Dividends, buybacks and share count

Acadia Pharmaceuticals returned $0.0M to shareholders in fiscal 2025, 0% of free cash flow. The diluted share count rose 2.1%.

Dividends and buybacks
Dividends Buybacks
Dividends and buybacks
Dividends Buybacks
Diluted shares outstanding (annual)

Value Acadia Pharmaceuticals yourself

Change the assumptions and see what they imply per share. These are models, not forecasts or price targets — the answer depends entirely on what you put in.

Discounted cash flow

Value per share

—

Adds net cash of — and divides by 169.9M diluted shares. Ten years of cash flows plus a terminal value, discounted to today.

Earnings multiple

Value per share

—

Reference multiples: today 8.8x · peers 17.1x · sector 28.4x.

Balance sheet

Cash, debt and the ratios that show how comfortably Acadia Pharmaceuticals can carry it.

Cash vs debt (incl. leases)
Cash Debt
Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments $521M$417M$439M$756M$820M
Current ratio 6.4x4.0x2.4x2.4x3.8x
Quick ratio 6.3x4.0x2.3x2.1x3.4x
Total assets $700M$588M$749M$1.2B$1.6B
Total liabilities $159M$187M$317M$455M$337M
Shareholders' equity $541M$400M$432M$733M$1.2B
Net debt (− = net cash) —————

Insider trades

Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.

Bought, 12 months

$0.0M

0 insiders

Sold, 12 months

$2.0M

4 insiders

Of sales under plans

94%

$1.8M

DateInsiderTradeSharesPriceValueFiling
Aug 6, 2026 Mark C. SchneyerEVP, Chief Financial Officer Sold plan 14,292 $29.22 $0.4M Form 4
Aug 5, 2026 Mark C. SchneyerEVP, Chief Financial Officer Sold plan 5,849 $29.00 $0.2M Form 4
Jul 30, 2026 Elizabeth H.Z. ThompsonEVP, Head of Research & Dev Sold plan 16,558 $26.13 $0.4M Form 4
Jun 26, 2026 James KiharaPrincipal Accounting Officer Sold plan 11,421 $26.08 $0.3M Form 4
May 26, 2026 James KiharaPrincipal Accounting Officer Sold 5,401 $21.18 $0.1M Form 4
May 4, 2026 James KiharaPrincipal Accounting Officer Sold plan 1,332 $21.79 $0.0M Form 4
May 4, 2026 Mark C. SchneyerEVP, Chief Financial Officer Sold plan 3,506 $21.79 $0.1M Form 4
Apr 7, 2026 James KiharaPrincipal Accounting Officer Sold plan 1,030 $22.20 $0.0M Form 4
Apr 7, 2026 Mark C. SchneyerEVP, Chief Financial Officer Sold plan 2,709 $22.20 $0.1M Form 4
Mar 26, 2026 James KiharaPrincipal Accounting Officer Sold plan 1,109 $21.65 $0.0M Form 4
Mar 26, 2026 Mark C. SchneyerEVP, Chief Financial Officer Sold plan 3,208 $21.65 $0.1M Form 4
Mar 25, 2026 Adams Catherine OwenChief Executive Officer, Director Sold plan 11,641 $21.47 $0.2M Form 4

Piotroski F-score

Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.

TestFY23FY24FY25
Net income is positive ✕ ✓ ✓
Cash from operations is positive ✓ ✓ ✓
Return on assets rose ✓ ✓ ✓
Cash from operations exceeds net income ✓ ✕ ✕
Debt fell relative to assets — — —
Current ratio rose ✕ ✕ ✓
Share count didn't rise ✕ ✕ ✕
Gross margin rose ✕ ✕ ✓
Revenue rose relative to assets ✓ ✓ ✕
F-score — / 9— / 9— / 9
Accruals ratio −11.7%7.1%20.4%
Altman Z'' −6.64−0.053.79

Similar companies

Each company's latest fiscal year. Fiscal years end in different months, so periods don't line up exactly.

CompanyMarket capGrowthOp. marginFCF marginROICP/EF-score
Acadia Pharmaceuticals ACAD $3.4B 11.9% 9.8% 9.8% — 8.8x —
Indivior INDV $4.3B 4.3% 21.2% −7.5% — 12.4x 4 Compare →
ANI Pharmaceuticals ANIP $1.6B 43.8% 12.6% 19.4% 15.9% 15.7x 6 Compare →
Collegium Pharmaceutical COLL $746M 23.6% 23.0% 42.0% 53.4% 18.5x 6 Compare →
Alkermes ALKS $7.6B −5.3% 17.2% 32.6% — 114.8x — Compare →

10 years of figures

US$ millions unless stated. Hover a ratio's name for its definition.

Download CSV
Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue $17.3M $125M $224M $339M $442M $484M $517M $726M $958M $1.1B
Gross profit $14.3M $116M $211M $328M $432M $473M $507M $685M $876M $983M
Research and development $99.3M $149M $187M $240M $319M $239M $362M $352M $303M $329M
Operating income −$273M −$292M −$247M −$247M −$287M −$170M −$224M −$73.4M $231M $105M
Pretax income −$270M −$288M −$244M −$234M −$281M −$168M −$213M −$51.0M $258M $139M
Income tax $1.3M $1.1M $1.3M $0.9M $0.6M $0.4M $2.5M $10.2M $31.6M −$252M
Net income −$271M −$289M −$245M −$235M −$282M −$168M −$216M −$61.3M $227M $391M
Diluted EPS −$2.34 −$2.36 −$1.94 −$1.60 −$1.79 −$1.05 −$1.34 −$0.37 $1.36 $2.30
Diluted shares 0.12B 0.12B 0.13B 0.15B 0.16B 0.16B 0.16B 0.16B 0.17B 0.17B
Cash flow
Cash from operations −$208M −$218M −$168M −$151M −$136M −$126M −$114M $16.7M $158M $110M
Capital expenditure $1.5M $0.8M $2.1M $1.1M $7.6M $1.1M $0.0M $0.0M $0.5M $4.7M
Free cash flow −$210M −$219M −$170M −$152M −$144M −$127M −$114M $16.7M $157M $105M
Depreciation and amortization $1.8M $2.7M $3.0M $2.8M $2.9M $3.3M $2.0M $5.6M $15.9M $11.8M
Stock-based compensation $55.3M $75.5M $81.6M $82.3M $84.4M $63.6M $68.2M $66.4M $67.0M $52.1M
Acquisitions $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M
Share buybacks $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M
Dividends paid $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M
Dividends and buybacks $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M
Balance sheet
Cash and short-term investments $529M $341M $474M $697M $632M $521M $417M $439M $756M $820M
Finance lease liabilities $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M
Current assets $548M $374M $526M $760M $718M $618M $508M $616M $938M $1.1B
Current liabilities $42.6M $49.0M $59.6M $74.8M $106M $96.1M $126M $254M $395M $277M
Inventory $4.2M $5.2M $4.1M $6.3M $9.7M $14.1M $11.6M $40.4M $91.7M $111M
Property and equipment, net $3.1M $2.7M $3.3M $3.2M $9.2M $8.0M $6.0M $4.6M $4.2M $7.5M
Total assets $561M $385M $540M $783M $783M $700M $588M $749M $1.2B $1.6B
Total liabilities $42.7M $49.2M $61.1M $84.0M $156M $159M $187M $317M $455M $337M
Shareholders' equity $518M $335M $479M $699M $627M $541M $400M $432M $733M $1.2B
Margins
Gross margin 82.2% 92.7% 94.5% 96.7% 97.7% 97.8% 98.0% 94.3% 91.5% 91.7%
Operating margin −1,574.1% −234.1% −110.6% −72.7% −64.9% −35.2% −43.2% −10.1% 24.1% 9.8%
EBITDA margin −1,563.6% −231.9% −109.2% −71.9% −64.2% −34.5% −42.8% −9.3% 25.8% 10.9%
Net margin −1,565.9% −231.7% −109.6% −69.4% −63.7% −34.7% −41.8% −8.4% 23.6% 36.5%
FCF margin −1,211.2% −175.0% −75.8% −44.9% −32.5% −26.2% −22.1% 2.3% 16.4% 9.8%
Returns
Return on capital employed −75.9% −68.5% −60.6% −41.5% −41.4% −26.6% −41.9% −15.3% 35.9% 10.1%
Return on equity −75.6% −67.8% −60.2% −39.9% −42.5% −28.8% −45.9% −14.7% 38.9% 39.9%
Return on assets −69.3% −61.2% −53.0% −35.6% −36.0% −22.6% −33.5% −9.2% 23.4% 28.4%
Growth
Revenue growth 28,311.5% 620.7% 79.2% 51.5% 30.3% 9.6% 6.8% 40.5% 31.9% 11.9%
Net income growth — — — — — — — — — 72.7%
EPS growth — — — — — — — — — 69.1%
FCF growth — — — — — — — — 844.0% −33.1%
Share count change 15.1% 5.8% 3.3% 16.3% 6.9% 2.0% 0.7% 1.3% 1.6% 2.1%
Financial health
Current ratio 12.9x 7.6x 8.8x 10.2x 6.8x 6.4x 4.0x 2.4x 2.4x 3.8x
Quick ratio 12.8x 7.5x 8.8x 10.1x 6.7x 6.3x 4.0x 2.3x 2.1x 3.4x
Capital allocation
Capex / revenue 8.7% 0.7% 0.9% 0.3% 1.7% 0.2% 0.0% 0.0% 0.1% 0.4%
Stock comp / revenue 318.9% 60.5% 36.4% 24.3% 19.1% 13.1% 13.2% 9.1% 7.0% 4.9%
Payouts / FCF — — — — — — — 0.0% 0.0% 0.0%
Quality scores
Altman Z'' 10.0 −2.8 2.0 5.3 −1.4 −3.2 −9.2 −6.6 −0.1 3.8
Accruals ratio −16.1% −15.2% −16.8% −12.7% −18.6% −5.7% −15.8% −11.7% 7.1% 20.4%

Source: SEC EDGAR XBRL filings (CIK 0001070494). Data updated October 22, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.

↑ ↓ to move · ↵ to open